Journal editorial - The emerging story of Myval transcatheter heart valve: lessons from the LANDMARK trial
ESC Cardio Talk
00:00
Hemodynamic device success results
Marie-Annick reports device success rates: Myval ~86%, Sapien 78%, Evolut 85%, noting overall parity.
Play episode from 01:29
Transcript
